Michael Sultan, MD
Interventional Cardiology · Bend, ORNPI 1538505326
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Abiomed at 31.1% of the total. Reporting peaked in 2019 at $2,416 and has fallen 87.8% since, to $294 in 2025.
Across 89 payments — averaging $59.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Medtronic$893
- Boston Scientific$519
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$374
- Abbott$312
- AstraZeneca$212
- plus $1K from 15 others
What the payments were for
- Food & beverage$5,282100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 21 | $1,641 |
| Medtronic(2 entities) | 17 | $893 |
| Boston Scientific | 8 | $519 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $374 |
| Abbott | 5 | $312 |
| AstraZeneca | 1 | $212 |
| Philips North America LLC | 3 | $159 |
| Johnson & Johnson | 3 | $156 |
| Penumbra, Inc. | 1 | $155 |
| Impulse Dynamics (USA) Inc. | 1 | $152 |
| Shockwave Medical, Inc | 1 | $127 |
| Acist Medical Systems, Inc. | 1 | $127 |
| Terumo Medical Corporation | 2 | $114 |
| Teleflex LLC | 2 | $111 |
| Amgen | 2 | $73 |
| Boehringer Ingelheim | 3 | $61 |
| Pfizer | 2 | $32 |
| Chiesi USA, Inc. | 1 | $19 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Biosense Webster, Inc. | 1 | $15 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,016
- OPTIMIZER$304
- Resolute$253
- Indigo System$155
- Azure$137
- Optis Coronary Imaging System$130
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$127
- MitraClip$127
- CVI SYSTEMS$127
- WATCHMAN Access System$121
- GENERAL - THERAPIES$119
- XARELTO$119
- GENERAL - STENTS$115
- Claria MRI$106
- SYMPLICITY G3$100
How this compares
$5,282 in reported general payments places this provider in the 55th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 289 | $348,450 |
| EntrestoSacubitril/Valsartan | 83 | $100,435 |
| JardianceEmpagliflozin | 71 | $65,392 |
| Repatha SureclickEvolocumab | 71 | $64,663 |
| XareltoRivaroxaban | 44 | $60,819 |
| FarxigaDapagliflozin Propanediol | 20 | $21,178 |
| Praluent PenAlirocumab | 15 | $9,564 |
| Rosuvastatin Calcium | 367 | $6,431 |
| Metoprolol Succinate | 407 | $6,210 |
| Ezetimibe | 126 | $3,796 |
| Atorvastatin Calcium | 242 | $3,536 |
| Losartan Potassium | 175 | $1,927 |
| Ranolazine ErRanolazine | 28 | $1,708 |
| ClopidogrelClopidogrel Bisulfate | 136 | $1,647 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 129 | $1,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $348,450289 claims |
| Boehringer IngelheimJardiance | $61 | $65,39271 claims |
| Johnson & JohnsonXarelto | $156 | $60,81944 claims |
| AstraZenecaFarxiga | $212 | $21,17820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Bend
- Saurabh GuptaBend$550K
- Erinn HughesBend$14K
- Nicholas BussBend$7K
- Alexander OchmanBend$6K
- Bruce McLellanBend$4K
- Allen RafaelBend$3K
- Michael WidmerBend$2K
- Jason WollmuthPortland$749K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.